Serum rituximab levels and efficiency of b cell depletion: Differences between patients with rheumatoid arthritis and systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 52, Issue 5, 2013, Pages 951-952

  Reddy, Venkat ^a   Croca, Sara ^a   Gerona, Delia ^b   De La Torre, Inmaculada ^b   Isenberg, David ^a   McDonald, Vickie ^a   Leandro, Maria ^a   Cambridge, Geraldine ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CYCLOPHOSPHAMIDE; RITUXIMAB;

B LYMPHOCYTE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LETTER; LYMPHOCYTE COUNT; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84876740605     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket004     Document Type: Letter

References (7)

1. Albert D, Dunham J, Khan S et al. Variability in the biological response to anti CD20 B cell depletion insystemic lupus erythaematosus. Ann Rheum Dis 2008;67: 1724-31.
2. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61: 883-8.
3. Vital EM, Dass S, Buch MH et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011;63:3038-47.
4. Vital EM, Rawstron AC, Dass S et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011;63: 603-8.
5. Vital EM, Dass S, Rawstron AC et al. Management of nonresponse to rituximab in rheumatoid arthritis: pre-dictors and outcome of re-treatment. Arthritis Rheum 2010;62:1273-9.
6. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
7. Lim SH, Vaughan AT, Ashton-Key M et al. Fc gamma re-ceptor IIb on target B cells promotes rituximab internal-ization and reduces clinical efficacy. Blood 2011;118: 2530-40.